Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
META 10-19 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07689604Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence and severity of adverse events at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Meta10-19
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07689604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689604.